These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 17589293

  • 1. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
    Zehbe I, Kaufmann AM, Schmidt M, Hohn H, Maeurer MJ.
    J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
    [Abstract] [Full Text] [Related]

  • 2. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 3. CD8+CD45RA+CD27-CD28-T-cell subset in PBL of cervical cancer patients representing CD8+T-cells being able to recognize cervical cancer associated antigens provided by HPV 16 E7.
    Pilch H, Hoehn H, Schmidt M, Steiner E, Tanner B, Seufert R, Maeurer M.
    Zentralbl Gynakol; 2002 Jan 01; 124(8-9):406-12. PubMed ID: 12655469
    [Abstract] [Full Text] [Related]

  • 4. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.
    Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH.
    Cancer Res; 2007 Jan 01; 67(1):354-61. PubMed ID: 17210718
    [Abstract] [Full Text] [Related]

  • 5. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
    de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Löwik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter GG, van der Burg SH.
    Cancer Res; 2010 Apr 01; 70(7):2707-17. PubMed ID: 20233872
    [Abstract] [Full Text] [Related]

  • 6. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
    Hara M, Matsueda S, Tamura M, Takedatsu H, Tanaka M, Kawano K, Mochizuki K, Kamura T, Itoh K, Harada M.
    Int J Oncol; 2005 Nov 01; 27(5):1371-9. PubMed ID: 16211234
    [Abstract] [Full Text] [Related]

  • 7. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
    Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S.
    Cancer Res; 2000 Jan 15; 60(2):365-71. PubMed ID: 10667589
    [Abstract] [Full Text] [Related]

  • 8. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PL.
    Gynecol Oncol; 2001 Jun 15; 81(3):424-32. PubMed ID: 11371133
    [Abstract] [Full Text] [Related]

  • 9. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jayaprabhu S, Pecorelli S, Parham GP, Cannon MJ.
    Clin Cancer Res; 2001 Mar 15; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [Abstract] [Full Text] [Related]

  • 10. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ.
    Clin Cancer Res; 2008 Jan 01; 14(1):169-77. PubMed ID: 18172268
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone.
    Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M.
    Cancer Immun; 2006 Jun 30; 6():9. PubMed ID: 16808432
    [Abstract] [Full Text] [Related]

  • 14. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
    Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Liénard D, Keilholz U.
    Cancer Res; 2002 Mar 15; 62(6):1743-50. PubMed ID: 11912149
    [Abstract] [Full Text] [Related]

  • 15. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S, Akatsuka Y, Nawa A, Kondo E, Kiyono T, Torikai H, Nakanishi T, Ito Y, Tsujimura K, Iwata K, Ito K, Kodera Y, Morishima Y, Kuzushima K, Takahashi T.
    Int J Cancer; 2007 Feb 01; 120(3):594-604. PubMed ID: 17096336
    [Abstract] [Full Text] [Related]

  • 16. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K, Leggatt GR, Zhong J, Liu X, de Kluyver RL, Peters T, Fernando GJ, Liem A, Lambert PF, Frazer IH.
    J Natl Cancer Inst; 2004 Nov 03; 96(21):1611-9. PubMed ID: 15523090
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.
    Cancer Res; 2003 May 15; 63(10):2535-45. PubMed ID: 12750277
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH, Jin HT, Park SH, Youn JI, Sung YC.
    Vaccine; 2009 Sep 25; 27(42):5906-12. PubMed ID: 19651174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.